LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

New Groundbreaking COVID-19 Test to Identify SARS-CoV-2 Virus Particles in Exhaled Breath Within Five Minutes

By LabMedica International staff writers
Posted on 27 Oct 2020
Image: New Groundbreaking COVID-19 Test to Identify SARS-CoV-2 Virus Particles in Exhaled Breath Within Five Minutes (Photo courtesy of Imec)
Image: New Groundbreaking COVID-19 Test to Identify SARS-CoV-2 Virus Particles in Exhaled Breath Within Five Minutes (Photo courtesy of Imec)
Researchers are developing a SARS-CoV-2 test to identify positive cases and confirm whether someone is contagious in less than five minutes using a groundbreaking approach that will use virus particles in exhaled breath.

Imec (Leuven, Belgium) has begun developing the groundbreaking SARS-CoV-2 test that will identify the virus particles in a person's exhaled breath, unlike the current approaches (using blood, saliva, or a nasopharyngeal swab). The solution promises accurate identification of a contagious case in less than five minutes, enabling faster, easier, more comfortable, and larger-scale testing. Imec's solution consists of a sample collector and an analysis unit, both of which are being custom developed by Imec researchers. Researchers are focusing much of their attention on the sample collector, which will act as the aerosol (and virus particle) collector and support the solution's high-speed real-time quantitative (RT-q) PCR functionality.

“Merging these tasks using conventional technologies would be extremely hard to do. But thanks to our innovation capability when it comes to using silicon, we have developed a chip that effectively does both,” said Peter Peumans, CTO of Health Technologies at Imec. “Its silicon microscale PCR cavities make for thousands of impactors that allows us to capture the viral particles, while its powerful RT-qPCR functionality brings down the duration of the PCR effort from 50 to 5 minutes. Importantly as well, the standard silicon technology used to build this chip facilitates mass production at a low cost.”

"Provided positive results in our clinical studies, our tool will make testing for SARS-CoV-2 easier, faster, more comfortable, and possible on a much larger scale. Moreover, we are designing our test to flexibly cope with the rise of other viruses and germs that spread via exhaled particles – such as influenza, RSV, and tuberculosis," added Peumans.

“It is now clear that the virus is transmitted pre-symptomatically via exhaled particles,” said Peter Piot, microbiologist and member of the European Commission advisory panel on COVID-19. “SARS-CoV-2 testing via breath sample coupled with an ultrafast molecular analysis would be game-changing since it would allow for the timely detection of individuals who are most likely to transmit the virus. Because a breath sample is much less invasive compared to swabs or saliva, it would also allow for more frequent testing and a faster return to normal.”

Related Links:
Imec

Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Laboratory Software
ArtelWare

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more